• SPX
  • $5,719.79
  • 0.35 %
  • $19.85
  • DJI
  • $42,032.59
  • 0.05 %
  • $21.00
  • N225
  • $38,635.62
  • 0.22 %
  • $83.56
  • FTSE
  • $8,295.32
  • 0.15 %
  • $12.80
  • IXIC
  • $17,985.69
  • 0.38 %
  • $67.21
Comera Life Sciences Holdings, Inc. (CMRA) Stock Price, News & Analysis

Comera Life Sciences Holdings, Inc. (CMRA) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.02

-$0

(0%)

Day's range
$0.02
Day's range
$0.02
50-day range
$1.0E-6
Day's range
$0.0305
  • Country: US
  • ISIN: US20037C1080
52 wk range
$0.02
Day's range
$0.47
  • CEO: Mr. Michael G. Campbell CPA
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -28.26
  • Piotroski Score 3.00
  • Grade N/A
  • Symbol (CMRA)
  • Company Comera Life Sciences Holdings, Inc.
  • Price $0.02
  • Changes Percentage (0%)
  • Change -$0
  • Day Low $0.02
  • Day High $0.02
  • Year High $0.47

Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform, SQore. Its SQore platform is designed to enable the conversion of intravenous (IV) biologics to subcutaneous (SQ) versions. The company is advancing its primary product programs, CLS-001, a preclinical stage biobetter for Crohn's and Ulcerative Colitis disease, and CLS-002, a preclinical stage biobetter for various oncology indications. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/09/2023
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$0.22
  • Trailing P/E Ratio -0.1
  • Forward P/E Ratio -0.1
  • P/E Growth -0.1
  • Net Income $-24,038,181

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.